Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

Y0002098

Sorafenib

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C21H16ClF3N4O3
Número de CAS:
284461-73-0
Peso molecular:
464.82
Número MDL:
MFCD06411450
Código UNSPSC:
41116107
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

sorafenib

fabricante / nombre comercial

EDQM

aplicaciones

pharmaceutical

Formato

neat

temp. de almacenamiento

2-8°C

cadena SMILES

FC(F)(F)c1c(ccc(c1)NC(=O)Nc2ccc(cc2)Oc3cc(ncc3)C(=O)NC)Cl

InChI

1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)

Clave InChI

MLDQJTXFUGDVEO-UHFFFAOYSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Sorafenib EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Pictogramas

Health hazardEnvironment
GHS08,GHS09

Palabra de señalización

Danger

Frases de peligro

H360FD,H362,H372,H410

Clasificaciones de peligro

Aquatic Acute 1 - Aquatic Chronic 1 - Lact. - Repr. 1B - STOT RE 1

Código de clase de almacenamiento

6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Baoxin Zhao et al.
Virologica Sinica, 38(5), 680-689 (2023-06-19)
Chronic hepatitis B virus (HBV) infection is one of the leading causes of hepatocellular carcinoma (HCC). The HBV genome is prone to mutate and several variants are closely related to the malignant transformation of liver disease. G1896A mutation (G to
Ye Kuang et al.
Cancer medicine, 12(6), 7222-7233 (2022-11-25)
Hepatocellular carcinoma (HCC) is a primary liver cancer with high mortality. The long-term use of sorafenib, a targeted drug for hepatocellular carcinoma, will lead to drug resistance, and patients are prone to cancer metastasis, the molecular mechanism of which is
Yiliang Wang et al.
Journal of nanobiotechnology, 22(1), 473-473 (2024-08-13)
Hepatocellular carcinoma (HCC) is a highly malignant tumor known for its hypoxic environment, which contributes to resistance against the anticancer drug Sorafenib (SF). Addressing SF resistance in HCC requires innovative strategies to improve tumor oxygenation and effectively deliver therapeutics. In
Zhong Wan et al.
Aging, 12(18), 18192-18208 (2020-10-07)
We investigated MAPK14-dependent resistance to sorafenib in hepatocellular carcinoma (HCC). Bioinformatics analysis and dual luciferase reporter assays in HCC cell lines showed that miR-216a-3p directly binds to the 3'UTR of MAPK14 mRNA and downregulates MAPK14 protein expression. Consequently, miR-216a-3p expression
Su-Hong Chen et al.
Experimental and therapeutic medicine, 23(3), 232-232 (2022-03-01)
Sorafenib is currently used to treat hepatocellular carcinoma (HCC). However, the development of chemoresistance to sorafenib is a major limitation for sorafenib-based therapy in patients with HCC. In the present study, the effect of the combination therapy of sorafenib and

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico